SiSaf is a private company supported by venture capital investors including Vickers Venture Partners and the UK Future Fund.
Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze